Contrast media reactions rarely happen, study finds
Concerns about the potential adverse reactions of patients to iodinated and gadolinium-based contrast agents used with CT and MRI may be more perceived than real, according to Mayo Clinic researchers.
Concerns about the potential adverse reactions of patients to iodinated and gadolinium-based contrast agents used with CT and MRI may be more perceived than real, according to Mayo Clinic researchers.
Dr. Christopher H. Hunt and colleagues in Rochester, MN, reviewed 456,930 episodes of contrast media administration. From this base, 522 cases of mostly mild adverse effects were identified. Reactions included nausea, vomiting, and skin rashes. Only 16 cases, 10 severe reactions to low-osmolar iodinated agents and six to gadolinium, needed transfer to an emergency department for further observation and treatment. One patient died, but possibly due to unrelated causes. Pretreatment with corticosteroids helped bring down the incidence of adverse effects (AJR 2009;193[4]:1124-1127). Adverse contrast reactions can occur, but they are rarely severe and most require only observation and supportive care, Hunt said.
FDA Clears Enhanced MRI-Guided Laser Ablation System
June 5th 2025An alternative to an open neurosurgical approach, the Visualase V2 MRI-Guided Laser Ablation System reportedly utilizes laser interstitial thermal therapy (LITT) for targeted soft tissue ablation in patients with brain tumors and focal epilepsy.
Can Abbreviated MRI Have an Impact in Differentiating Intraductal Papilloma and Ductal Secretion?
June 3rd 2025For patients with inconclusive ultrasound results, abbreviated breast MRI offers comparable detection of intraductal papilloma as a full breast MRI protocol at significantly reduced times for scan acquisition and interpretation, according to a new study.
Can AI Assessment of PET Imaging Predict Treatment Outcomes for Patients with Lymphoma?
June 2nd 2025The use of adjunctive AI software with pre-treatment PET imaging demonstrated over a fourfold higher likelihood of predicting progression-free survival (PFS) in patients being treated for lymphoma, according to a new meta-analysis.
